Biotech & Life Sciences

AnaptysBio is splitting itself in two — and betting that Wall Street will value each half more than the sum of the whole. The San Diego biotech announced Thursday that its board has approved a spin-off of First Tracks Biotherapeutics, a clinical-stage immunology company that will begin regular-w...

China is winning the race to remake medicine, and Washington is running out of time to catch up.

The FDA approved Awiqli, Novo Nordisk's once-weekly basal insulin, on March 26, 2026.

When two ovarian cancer patients get the same dose of the same drug, you would expect similar outcomes.

Your gut is not a peaceful place.

Every patient in the trial had a serious adverse event.

The British-Swedish drugmaker AstraZeneca published positive Phase 3 results Friday for tozorakimab, an anti-IL-33 antibody, in chronic obstructive pulmonary disease — and the interesting part is not the win.

When your best drug makes $30 billion a year and its patent expires in two, you buy.

Allogene Therapeutics is about to bet its entire future on twelve people in each arm. In April 2026, the South San Francisco company will unblind a 24-patient interim snapshot from its ALPHA3 trial, split evenly between patients receiving cemacabtagene ansegedleucel — its off-the-shelf anti-CD19...

Most mass spectrometers work like trying to catch fish from Niagara Falls with a single bucket.

When a parasitic worm takes up residence in your gut, your body takes a few days to decide it is actually a problem worth acting on.